Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning

被引:42
作者
Morofuji, Yoichi [1 ]
Nakagawa, Shinsuke [2 ]
机构
[1] Nagasaki Univ, Dept Neurosurg, Grad Sch Biomed Sci, 1-7-1 Sakamoto, Nagasaki 8528501, Japan
[2] Nagasaki Univ, Dept Med Pharmacol, Grad Sch Biomed Sci, 1-12-4 Sakamoto, Nagasaki 8528523, Japan
关键词
Blood-brain barrier; central nervous system disease; drug development; drug repositioning; neurotherapeutics; penetration efficacy; MICROVASCULAR ENDOTHELIAL-CELLS; MEMBRANE-PERMEABILITY ASSAY; EXPERIMENTAL CEREBRAL-ISCHEMIA; ALZHEIMERS-DISEASE; ENDOVASCULAR TREATMENT; ELECTRICAL-RESISTANCE; VASCULAR PROTECTION; PARKINSONS-DISEASE; NEUROVASCULAR UNIT; REPURPOSED DRUGS;
D O I
10.2174/1381612826666200224112534
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
An important goal of biomedical research is to translate basic research findings into practical clinical implementation. Despite the advances in the technology used in drug discovery, the development of drugs for central nervous system diseases remains challenging. The failure rate for new drugs targeting important central nervous system diseases is high compared to most other areas of drug discovery. The main reason for the failure is the poor penetration efficacy across the blood-brain barrier. The blood-brain barrier represents the bottleneck in central nervous system drug development and is the most important factor limiting the future growth of neurotherapeutics. Meanwhile, drug repositioning has been becoming increasingly popular and it seems a promising field in central nervous system drug development. In vitro blood-brain barrier models with high predictability are expected for drug development and drug repositioning. In this review, the recent progress of in vitro BBB models and the drug repositioning for central nervous system diseases will be discussed.
引用
收藏
页码:1466 / 1485
页数:20
相关论文
共 230 条
  • [1] Novartis to shut brain research facility
    Abbott, Alison
    [J]. NATURE, 2011, 480 (7376) : 161 - 162
  • [2] Blood-brain barrier structure and function and the challenges for CNS drug delivery
    Abbott, N. Joan
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2013, 36 (03) : 437 - 449
  • [3] Astrocyte-endothelial interactions at the blood-brain barrier
    Abbott, NJ
    Rönnbäck, L
    Hansson, E
    [J]. NATURE REVIEWS NEUROSCIENCE, 2006, 7 (01) : 41 - 53
  • [4] Vascular bed-specific thrombosis
    Aird, W. C.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 : 283 - 291
  • [5] Selective drug delivery approaches to lesioned brain through blood brain barrier disruption
    Al-Ahmady, Zahraa S.
    [J]. EXPERT OPINION ON DRUG DELIVERY, 2018, 15 (04) : 335 - 349
  • [6] Pericytes: Cell biology and pathology
    Allt, G
    Lawrenson, JG
    [J]. CELLS TISSUES ORGANS, 2001, 169 (01) : 1 - 11
  • [7] A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413
    Amano, Masayuki
    Salcedo-Gomez, Pedro Miguel
    Zhao, Rui
    Yedidi, Ravikiran S.
    Das, Debananda
    Bulut, Haydar
    Delino, Nicole S.
    Sheri, Venkata Reddy
    Ghosh, Arun K.
    Mitsuya, Hiroaki
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (12) : 7046 - 7059
  • [8] Three-Dimensional Cell Culture: A Breakthrough in Vivo
    Antoni, Delphine
    Burckel, Helene
    Josset, Elodie
    Noel, Georges
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (03): : 5517 - 5527
  • [9] Neurovascular unit crosstalk: Pericytes and astrocytes modify cytokine secretion patterns of brain endothelial cells
    Banks, William A.
    Kovac, Andrej
    Morofuji, Yoichi
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2018, 38 (06) : 1104 - 1118
  • [10] From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery
    Banks, William A.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (04) : 275 - +